Skip to main content
  • Poster presentation
  • Open access
  • Published:

Two cases of multiple-drug-resistant adult-onset Still's disease treated successfully with tocilizumab - the relationship between interleukin 6 and 18

Background

Adult-onset Still's disease (AOSD) is an inflammatory disease of unknown cause characterized by a high spiking fever, arthritis and evanescent rash. The mainstay of treatment is glucocorticoids with or without immunosuppressants. Recently, biologics such as anti-tumor necrosis factor (TNF) antibodies have also been tried in certain refractory cases.

Results

We have had two cases of AOSD which were treated successfully with anti-interleukin (IL-) 6-receptor antibody, tocilizumab (TOC). (Case 1) A 36-year-old woman who was diagnosed 8 years previously, and had been treated with various DMARDs plus etanercept (ETA) or adalimumab, presented with a high spiky fever and elevated liver enzymes. After excluding infection, she was treated with TOC. (Case 2) A 26-year-old man with new-onset AOSD, which was shown to be resistant to multiple immunosuppressants including infliximab and ETA, was treated with TOC starting 7 months after the diagnosis. In both cases, serum IL-18 was extremely high, and TOC promptly improved clinical symptoms and liver function. The high level of serum ferritin also became normalized. Interestingly, especially in case 2, the level of IL-18 remained high after the administration of TOC, suggesting that IL-18 is located either upstream of, or at the same level as, IL-6 in the pathogenesis of AOSD. Next, we cultured human monocytes derived from healthy controls with or without the presence of IL-6 and/or IL-18 in vitro. The level of ferritin in the supernatant was significantly increased only when both IL-6 and IL-18 were added, indicating that IL-6 and IL-18 have a synergistic effect on the production of ferritin (Figure 1).

Figure 1
figure 1

The level of ferritin in the supernatant of monocytes cultured with or without the presence of IL-6 and/or IL-18 (10 ng/mL each)

Conclusion

TOC can be a first-line biologic applicable against multiple-drug-resistant AOSD. If an IL-18 blocker is developed, however, it may be even more beneficial in that it may block the cascade of inflammation at a point further upstream.

Author information

Authors and Affiliations

Authors

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Cite this article

Sato, K., Yamamoto, A., Yoshida, Y. et al. Two cases of multiple-drug-resistant adult-onset Still's disease treated successfully with tocilizumab - the relationship between interleukin 6 and 18. Arthritis Res Ther 14 (Suppl 1), P62 (2012). https://doi.org/10.1186/ar3663

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/ar3663

Keywords